

THE PREVENTION OF DEEP VENOUS THROMBOSIS

Original Release/Approval	25 Dec 2004	Note: This CPG requires an annual review.	
Reviewed:	Nov 2008	Approved:	21 Nov 2008
Supersedes:	The Prevention of Deep Vein Thrombosis, updated Apr 2008		

1. Goal. To establish guidance for anti-thrombotic therapy for the prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in combat casualties.

2. Background.

- a. American College of Chest Physicians Conference recommended that, “every hospital should develop a written policy or other formal strategy for preventing thromboembolic complications, especially for high-risk patients.”
- b. Proximal deep venous thrombosis (DVT) continues to be a frequent complication in hospitalized patients. Pulmonary embolism, a very serious potential outcome from DVT, has been seen in over 20% of patients hospitalized with DVTs in national reviews and is a major cause of morbidity and mortality in these patients.
- c. There is an increasing recognition of DVT in individuals who complete an extended period of travel on an airplane. One study noted a 10% prevalence of asymptomatic DVT in individuals undergoing flights of 8 hours or more. Landstuhl Regional Medical Center is uniquely positioned to receive patients who have undergone extensive periods of travel prior to admission.
- d. Different medical societies and working groups have published varying recommendations for DVT prophylaxis. Where these recommendations disagree, the clinical guidelines recommended here represent the guideline with either a higher level of scientific evidence supporting the recommendation, or the more conservative recommendation.
- e. Due to the increasingly short aeromedical evacuation times achieved in our system today, it may be possible that certain patients will still be receiving blood product therapy to correct coagulopathy when they enter the chain. It is inherent on providers at each step in the aeromedical evacuation chain to evaluate patients for DVT prophylaxis and make adjustments in therapy as clinically appropriate. ***It is recommended to begin DVT prophylaxis therapy as soon as coagulopathy is corrected in patients not otherwise at increased risk of bleeding.***

3. Education and Treatment.

See Appendix A for specific guidance on different subsets of patients after various surgical procedures.

4. Responsibilities.

- a. All Health Care Providers will:
 - 1) Become familiar with the guidelines for the prevention of DVT (see Appendix A).
 - 2) Appropriately manage patients who may be at risk of developing DVT.

Joint Theater Trauma System Clinical Practice Guideline

- 3) Provide feedback on these guidelines and suggestions for changes to the CPG to the JTTS Theater Trauma Director.
- b. The Senior surgeon and/or Intensivist at each Level III facility will:
 - 1) Review all thromboembolic events in the Level III facility to assess ways to reduce the risk to the patient.
 - 2) Coordinate with the Theatre Trauma Coordinator on the appropriateness of the guidelines being used and provide input for updates on an as needed basis.

5. References.

- ¹ The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines, Chest; 126:3(Supplement), September 2004
- ² Practice Management Guidelines for the Management of Venous Thromboembolism in Trauma Patients, Eastern Association for the Surgery of Trauma, www.east.org, May 8, 2006
- ³ Scurr JH; Machin SJ; Bailey-King S; Mackie IJ; McDonald S; Smith PD, "Frequency and Prevention of Symptom-less Deep Venous Thrombosis in Long Haul Flights: A Randomized Trial, Lancet 357:1485-9, 2001
- ⁴ Knudson MM, Morabito D, Paiement GD, et al: Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 41:446-59, 1996
- ⁵ Knudson MM, Lewis FR, Clinton A, et al: Prevention of venous thromboembolism in trauma patients. J Trauma 37:480-7, 1994
- ⁶ Geerts WH, Code KJ, Jay RM, et al: A prospective study of venous thromboembolism after major trauma. N Engl J Med 331:1601-6, 1994
- ⁷ Geerts WH, Jay RM, Code KJ, et al: A comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 335:701-7, 1996
- ⁸ Knudson MM: Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004: 490-6

Approved by CENTCOM JTTS Director and Deputy
Director and CENTCOM SG

Opinions, interpretations, conclusions, and recommendations are those of the authors
and are not necessarily endorsed by the Services or DoD.

Guideline Only/Not a Substitute for Clinical Judgment
November 2008

APPENDIX A

GUIDELINES FOR PREVENTION OF DEEP VEIN THROMBOSIS	
<u>Risk Group</u>	<u>Prophylactic Measures</u>
TRAUMA SURGERY	
Emergency trauma surgical procedures in patients with prohibitive risk of bleeding, or ongoing coagulopathy	SCD (sequential compression device) until able to be anticoagulated (ideally start Lovenox within 12 hours of cessation of coagulopathy); see IVC filter and Duplex screening sections below.
Emergency trauma surgical procedures in all patients, except patient with prohibitive risk of bleeding (once coagulopathy not present)	Lovenox 30 mg BID; <i>strongly</i> consider adding SCD
Isolated major orthopedic surgery of extremities, spine, and pelvis	SCD + Lovenox 30 mg BID; See IVC filter section below Continue tx for 7-10 days post-op
IVC FILTER PLACEMENT*	
<p>Patients with:</p> <ol style="list-style-type: none"> 1. Recurrent PE despite full anticoagulation 2. Proximal DVT and contraindications for full anticoagulation 3. Proximal DVT and major bleeding while on full anticoagulation 4. Progression of iliofemoral clot despite anticoagulation <p>Patients with established DVT or PE and:</p> <ol style="list-style-type: none"> 1. Large free-floating thrombus in the iliac vein or IVC 2. Following massive PE in which recurrent emboli may prove fatal 3. During/after surgical embolectomy 	<p>Level I evidence for placement of IVC filter</p> <p>* removable filters preferred; document carefully in record and TMDS; PE may still occur despite IVC filter</p> <p>Level II evidence for “extended” indications for prophylactic IVC filter for patients with established DVT or PE</p>

Joint Theater Trauma System Clinical Practice Guideline

GUIDELINES FOR PREVENTION OF DEEP VENOUS THROMBOSIS

<u>Risk Group</u>	<u>Prophylactic Measures</u>
<p>Very High Risk Patients: those who cannot receive anticoagulation because of increased bleeding risk and :</p> <ol style="list-style-type: none"> 1. Severe closed head injury (GCS<8) 2. Incomplete spinal cord injury with paraplegia or quadriplegia 3. Complex pelvic fractures with associated long-bone fractures 4. Multiple long-bone fractures 	<p>Level III evidence for consideration of placement of prophylactic placement of IVC filter. Impact of retrievable filters is unclear in this patient population</p>

ROLE OF DUPLEX SCREENING

Asymptomatic patients	Serial duplex ultrasound imaging of high-risk patients may be cost-effective and decrease the incidence of PE (Level III)
Symptomatic patients	Duplex ultrasound may be used without confirmatory venography (Level I)

GENERAL SURGERY

<u>Low Risk:</u>	
<ul style="list-style-type: none"> – minor procedure in patients < 40 years, no risk factors 	Early mobilization
<u>Moderate Risk:</u>	
<ul style="list-style-type: none"> – minor procedure with additional risk factors for thrombosis; – non major surgery in patients 40-60 years, with no additional risk factors; – major surgery in patients < 40 years with no additional risk factors) 	Unfractionated Heparin 5000 units BID <i>or</i> Lovenox 40 mg QD
<u>Higher Risk:</u>	
<ul style="list-style-type: none"> – non major surgery in patients > 60 years or have additional risk factors; – major surgery in patients > 40 years or 	Unfractionated Heparin 5000 units TID <i>or</i> Lovenox 30 mg BID

Guideline Only/Not a Substitute for Clinical Judgment

November 2008

Joint Theater Trauma System Clinical Practice Guideline

GUIDELINES FOR PREVENTION OF DEEP VENOUS THROMBOSIS	
<u>Risk Group</u>	<u>Prophylactic Measures</u>
<p>have additional risk factors</p> <p style="text-align: center;"><u>High Risk:</u></p> <p>– patients with multiple risk factors</p> <p><u>Moderate Risk or Higher Patients with high risk of bleeding</u></p>	<p>Unfractionated Heparin 5000 units TID <i>or</i> Lovenox 30 mg BID plus GCS (graduated compression stocking) <i>or</i> SCD</p> <p>GCS or SCD</p>
VASCULAR SURGERY	
<p>Patients without additional thromboembolic risk factors</p> <p>Patients with additional thromboembolic risk factors</p>	<p>No need for thromboprophylaxis</p> <p>Unfractionated Heparin 5000 units BID <i>or</i> Lovenox 40 mg QD</p>
UROLOGIC SURGERY	
<p>Low Risk urologic procedures</p> <p>Major, open urologic procedures</p> <p>Patients actively bleeding or at risk for bleeding</p> <p>Patients with multiple risk factors</p>	<p>Early ambulation</p> <p>Unfractionated Heparin 5000 units BID or TID</p> <p>GCS or SCD</p> <p>GCS or SCD and Unfractionated Heparin 5000 units BID or TID or Lovenox 40 mg QD</p>
NEUROSURGERY	
<p>Intracranial neurosurgical procedures</p> <p>High Risk neurosurgery patients</p>	<p>SCD with or without GCS</p> <p>SCD and/or GCS</p> <p>OK to use Lovenox following stable CT scan in consultation with neurosurgeon</p>

Guideline Only/Not a Substitute for Clinical Judgment
November 2008

APPENDIX B

ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGs

A. Purpose.

The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.

B. Background.

Unapproved (i.e., “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command required, unapproved uses. Some command requested unapproved uses may also be subject to special regulations.

C. Additional Information Regarding Off-Label Uses in CPGs.

The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard of care.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.

D. Additional Procedures.

1. Balanced Discussion. Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.

2. Quality Assurance Monitoring. With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.

3. Information to Patients. Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.